Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis

Assessment Status Assessment Process Complete
Drug Rivaroxaban
Brand Xarelto®
Indication For the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.
Assessment Process
Rapid review commissioned 17/08/2011
Rapid review completed 31/08/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 28/11/2011
NCPE assessment completed 24/02/2012
NCPE assessment outcome Cost effective at submitted price

We consider that at the submitted price Rivaroxaban could be considered cost-effective for this indication.

Technical Summary